This is a prospective, multi-center, single-arm, pivotal study. The objective of this study is to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection during Transcarotid Artery Revascularization procedures using the CGuard Prime Carotid Stent System 80 in the treatment of carotid artery stenosis in patients at high risk for complications from CEA.
This study is a prospective, multi-center, single arm pivotal study. The study shall not be blinded prior to, during or following the procedure. Patients undergoing transcarotid artery revascularization will be screened against the study inclusion/exclusion criteria. If the patient meets study eligibility requirements, they shall be invited to participate, provided informed consent and shall subsequently be assigned a study ID number. Enrollment will be 103 pivotal patients. A maximum of 20% of patients will be enrolled at any single site. The total enrollment accounts for an estimate that up to 2 patients will exit the study prior to the 30-day primary endpoint assessment. An additional roll-in cohort of up to 2 patients per primary physician operator at each study site may also be accrued (maximum of 50 roll-in patients total, assuming one primary physician operator per site). This study does not duplicate any current knowledge existing today on use of the SwitchGuard NPS when used in conjunction with the CGuard Prime™ 80cm in the United States.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
103
The CGuard Prime™ 80 will be used in conjunction with the SwitchGuard™ NPS for the carotid artery stenting implantation procedure that will be performed by physician investigators experienced with transcarotid artery revascularization.
Composite primary endpoint
Incidence of the composite primary endpoint comprised of Death (all-cause mortality), all Stroke, or Myocardial Infarction (DSMI) through 30-days post-index procedure, based on Clinical Events Committee (CEC) adjudication.
Time frame: 30 days
Rate of all death within 30 days of the procedure
Time frame: 30 days
Rate of cardiac death within 30 days of the index procedure
Time frame: 30 days
Rate of neurological death within 30 days of the index procedure
Time frame: 30 days
Rate of all strokes within 30 days of the procedure
Time frame: 30 days
Rate of major stroke within 30 days of the procedure
Time frame: 30 days
Rate of minor stroke within 30 days of the procedure
Time frame: 30 days
Rate of ipsilateral stroke within 30 days of the procedure
Time frame: 30 days
Rate of MI within 30 days of the procedure
Time frame: 30 days
Composite of death or stroke rate within 30 days of the procedure
Time frame: 30 days
Rate of cranial nerve injury within 30 days of the procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 30 days
Access site complications (arterial/venous)
Time frame: At procedure
All device-related serious adverse events within 30 days of the procedure
Time frame: 30 days
Acute success for the SwitchGuard NPS
Successful insertion of the SwitchGuard NPS into the vasculature, followed by flow reversal, and the removal of the SwitchGuard NPS from the vasculature.
Time frame: At procedure
Acute success for CGuard Prime 80cm Delivery System and Stent
Successful insertion of the delivery system, successful deployment of the stent, and successful retraction of the delivery system when used in conjunction with the SwitchGuard NPS.
Time frame: At procedure
Technical Success for the CGuard Prime 80cm Delivery System and Stent
Technical Success Rate is defined as the number of patients with at least one CGuard Prime™ 80 device successfully delivered and deployed with final residual diameter stenosis \< 30% following final post-balloon dilatation (if performed) divided by the total number of patients where CGuard Prime™ 80 device deployment was attempted when used in conjunction with the SwitchGuard NPS during a TCAR procedure.
Time frame: At procedure
Procedural success
Acute device success for CGuard Prime 80cm Delivery System and Stent, AND acute device success for SwitchGuard NPS, AND freedom from the composite of death, all stroke or MI at 30-day post-procedure.
Time frame: 30 days
Treatment Success for the CGuard Prime 80cm Delivery System and Stent
Treatment Success Rate is defined as the number of patients who meet CGuard Prime™ 80 Technical Success Rate without experiencing death, stroke or MI through 30-day post-procedure, divided by the total number of patients where CGuard Prime™ 80 device deployment was attempted when used in conjunction with the SwitchGuard NPS during a TCAR procedure.
Time frame: 30 days